Axovant gets rights to gene therapies from UMass medical school

The University of Massachusetts Medical School (Worcester, Mass.) granted Axovant exclusive, worldwide rights to develop and commercialize two gene therapies to treat GM1 and GM2 gangliosidoses.

The school received $10 million up front and is eligible for $24.5 million in development and regulatory milestones as well as $39.8 million in commercial milestones, plus tiered mid-single-digit royalties...